



(51) International Patent Classification:

C07D 403/04 (2006.01) *A61P 29/00* (2006.01)
A61K 31/416 (2006.01)

(21) International Application Number:

PCT/US2012/026506

(22) International Filing Date:

24 February 2012 (24.02.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/446,732 25 February 2011 (25.02.2011) US
61/448,542 2 March 2011 (02.03.2011) US

(71) Applicant (for all designated States except US): **ARENA PHARMACEUTICALS, INC.** [US/US]; 6166 Nancy Ridge Drive, San Diego, California 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BLACKBURN, Anthony C.** [US/US]; 12633 Caminito Rosita, San Diego, California 92128 (US). **HAN, Sangdon** [KR/US]; 9953 Fieldthorn Street, San Diego, California 92127 (US). **JONES, Robert M.** [GB/US]; 10937 Corte luz del Sol, San Diego, California 92130 (US). **MONTALBAN, Anthony Garrido** [ES/US]; 10339 Azuaga Street, No. 213,

San Diego, California 92129 (US). **PAL, Biman B.** [US/US]; 8560 Foxcroft Place, San Diego, California 92129 (US). **RUETER, Jaimie Karyn** [US/US]; 9022 Westvale Road, San Diego, California 92129 (US).



(74) Agents: **SPRUCE, Lyle W.** et al.; Arena Pharmaceuticals, Inc., 6166 Nancy Ridge Drive, San Diego, California 92121 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF CONDENSED AZACYCLES (CANNABINOID RECEPTOR MODULATORS)



(57) Abstract: The present invention relates to crystalline forms of (1a*S*,5a*S*)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1*H*-2,3-diaza-cyclopropa[*a*]pentalene-4-carboxylic acid ((*S*)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB₂ receptor and are therefore useful in the treatment of CB₂ receptor-mediated disorders, for example, osteoarthritis; pain; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation for example; atherosclerosis; undesired immune cell activity, and inflammation associated with a disorder selected from: osteoarthritis, anaphylaxis, Behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis; and Parkinson's disease.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, **Published:**
GW, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*